louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03871101: Evaluation of Dental Anxiety in Second-Stage Implant Surgery With Er,Cr:YSGG Laser
Official title: Evaluation of Dental Anxiety in Patients Undergoing Second Stage Surgery With Er,Cr:YSGG Laser Treatment: Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dental Anxiety
Keywords: Dental Anxiety
STAI
Er,Cr:YSGG
oral surgery
Lead sponsor: Yuzuncu Yıl University
Sponsor class: OTHER
First posted: 2019-03-12
Enrollment: 96
Sex: ALL
Minimum age (years): 20
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Implants embedded under the oral mucosa were exposed with scalpel (Group 1) or laser surgery (Group 2). Before the operation the patients were asked to fill the State-Trait Anxiety Inventory (STAI) and Dental Anxiety Scale (DAS) while resting in the waiting room.


Eligibility criteria: Inclusion Criteria:

* patients undergoing second-stage implant surgery

Exclusion Criteria:

* Patients without sufficient keratinized gingiva
* Bone overlap on closure screw
* Implants that can not be localized due to gingiva thickness,

Primary outcomes:
measure: Dental anxiety
timeFrame: 20 minutes before the operation
measure: Dental Anxiety
timeFrame: 20 minutes before the operation
Secondary outcomes:
Other outcomes:
Locations:
city: Van
country: Turkey
facility: Van Yuzuncu Yil University Faculty of Dentistry
Study officials:
affiliation: Yuzuncu Yıl University
name: Ahmet C Talmac
role: STUDY_CHAIR
References:
citation: Candido MC, Andreatini R, Zielak JC, de Souza JF, Losso EM. Assessment of anxiety in patients who undergo surgical procedures for tooth implants: a prospective study. Oral Maxillofac Surg. 2015 Sep;19(3):253-8. doi: 10.1007/s10006-014-0480-3. Epub 2015 Jan 10.
citation: Kazancioglu HO, Dahhan AS, Acar AH. How could multimedia information about dental implant surgery effects patients' anxiety level? Med Oral Patol Oral Cir Bucal. 2017 Jan 1;22(1):e102-e107. doi: 10.4317/medoral.21254.
Clinical trial NCT05190601: Uroflowmetry in Children With Enuresis Nocturnal
Official title: How Valuable is Uroflowmetry in Children With Enuresis Nocturnal?
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Enuresis
Keywords: enuresis nocturna
uroflowmetry
child
Lead sponsor: Hisar Intercontinental Hospital
Sponsor class: OTHER
First posted: 2022-01-13
Enrollment: 180
Sex: ALL
Minimum age (years): 6
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pediatric,primary monosymptomatic enuresis nocturna, 6-16 years, without comorbidity

Brief summary: Background: Enuresis nocturna is an important social and psychological problem in children. Uroflowmetry is an important test used to investigate lower urinary tract symptoms..

Objective:To evaluate the uroflowmetry (UFM) results of children with nocturnal enuresis (NE).

Method:

The uroflowmetry findings of healthy and visualized children without any urinary symptoms and who were prospectively admitted to the urology and pediatric surgery outpatient clinic with the complaint of Enuresis nocturna between January 2020 and July 2021 were compared. Information (anamnesis, physical examination, radiology results and laboratory tests) and uroflowmetry results of NE and healthy children included in the study were recorded.

Detailed description: SMale and Female,

Eligibility criteria: Inclusion Criteria:

Primer monosymptomatic enuresis nocturna

Exclusion Criteria:

Urinary infectious Diabetes Spina bifida, Epispadias, Hipospadias VUR Extrophia Vesica Epilepsy Cerebral Palsy

Primary outcomes:
measure: uroflowmetry
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Hisar Intercontinental Hospital
Study officials:
References:
Clinical trial NCT05185401: Effects of Propofol-Induced Anaesthesia on the ST-segment of the ECG
Official title: Effects of Propofol-Induced Anaesthesia on the ST-segment of the ECG
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: No Specific Condition (Patients Without Brugada Syndrome)
Lead sponsor: Universitair Ziekenhuis Brussel
Sponsor class: OTHER
First posted: 2022-01-11
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adult patients who underwent a surgical procedure under propofol-based general anaesthesia in the CathLab of UZB.

Brief summary: The purpose of this study is to assess the effect of propofol induced general anaesthesia on the ST-segment of the electrocardiogram. This will be realised by retrospectively analysing the ECG-recordings from adult patients undergoing any treatment at the Catheterisation Laboratory. The ST-segment and other ECG measurements from induction of anaesthesia up to 20 minutes later, will be assessed and compared to the baseline values of the respective segments acquired before injecting propofol. It is essential in this study to exclude any patients burdened with the diagnosis, suspicion or family history of Brugada syndrome.


Eligibility criteria: Inclusion Criteria:

* Induction of anaesthesia with propofol
* Monitored anaesthesia in the CathLab of the Universitair Ziekenhuis Brussel

Exclusion Criteria:

* Brugada Syndrome or family history of Brugada syndrome
* Paediatric population (age \<18)
* Patients who did not receive propofol during the procedure
* Patients who presented with fever (central core temperature \>38,0°C)

Primary outcomes:
measure: ST-segment variations after propofol administration.
timeFrame: Baseline ECG will be measured before administration of propofol. ECG will be measured in the 20 minutes following administration of propofol
Secondary outcomes:
measure: Additional ECG-segment variations after propofol administration
timeFrame: Baseline ECG will be measured before administration of propofol. ECG will be measured in the 20 minutes following administration of propofol
Other outcomes:
Locations:
city: Brussel
country: Belgium
facility: Universitair Ziekenhuis Brussel
state: Brussels
Study officials:
References:
Clinical trial NCT03416101: Siewert Type II Esophageal Adenocarcinoma: Relationship Between Histology and Survival
Official title: Siewert Type II Esophageal Adenocarcinoma: on the Relationship Between Histology, Esophageal-gastric Intestinal Metaplasia and Gastric Greater Curvature Lymphatic Metastases, Survival
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Siewert Type II Adenocarcinoma of Esophagogastric Junction
Keywords: esophageal cancer
adenocarcinoma of the esophagus
esophageal surgery
Lead sponsor: University of Bologna
Sponsor class: OTHER
First posted: 2018-01-30
Enrollment: 154
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: One hundred fifty four Siewert type II cases were enrolled: 124 men (80.5%), 30 women (19.5%), median age 65.5 (interquartile range 58-71); Intestinal type 91 (59%) and Diffuse type 63 (41%).

Brief summary: In Siewert type II adenocarcinoma, the relationship between adenocarcinoma sub types and survival, histologic/biologic patterns related to the presence/absence of gastric greater curvature metastases, were investigated.

Detailed description: In order to achieve further data on the biological patterns of intestinal and diffuse subtypes of esophageal adenocarcinoma (Lauren's classification), on the frequency of gastric greater curvature nodal stations and on the clinical relevance, in terms of prognosis and survival, of these parameters, a Siewert type II case series of Siewert type II adenocarcinomas, submitted to primary (no neoadjuvant therapy) surgical, studied, operated upon and followed up, were analysed. According to histologic patterns, cases were ordered in intestinal and diffuse adenocarcinoma sub types (Lauren's classification)and distinguished in Barret's, cardiopyloric, gastric types.

Eligibility criteria: Inclusion Criteria:

Siewert type II adenocarcinoma \> 18 year submitted to primary surgery

Exclusion Criteria: Siewert type II adenocarcinoma submitted to neoadjuvant therapy.

Siewert type I adenocarcinoma. Siewert type III adenocarcinoma Squamous Carcinoma

-

Primary outcomes:
measure: Survival
timeFrame: 5 years
Secondary outcomes:
measure: Frequency of gastric greater curvature lymph nodes metastases in Siewert II adenocarcinoma
timeFrame: 5 years
Other outcomes:
Locations:
city: Bologna
country: Italy
facility: Department of Medical and Surgical Sciences University of Bologna
state: Bo
city: Bologna
country: Italy
facility: Sandro Mattioli - Alma Mater Studiorum-University
state: BO
Study officials:
affiliation: Department of Medical and Surgical Sciences
name: Sandro Mattioli - Alma M Studiorum-University, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04514601: A Quality Improvement Project to Assess and Refine the Handover Process at Morning Trauma Meetings
Official title: A Quality Improvement Project to Assess and Refine the Handover Process at Morning Trauma Meetings
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Neck of Femur Fracture
Fractures, Bone
Orthopedic Disorder
Lead sponsor: Sandwell & West Birmingham Hospitals NHS Trust
Sponsor class: OTHER
First posted: 2020-08-17
Enrollment: 317
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Trauma and Orthopaedic patients.

Brief summary: This project was intended to observe the handover of trauma and orthopaedic patients at a district general hospital in the UK. Following the implementation of a standard operating protocol, the handover of patient information improved including neck of femur fracture patients significantly. The study can therefore be utilised by other similarly structured departments to improve the handover process, thereby improving patient safety.

Detailed description: Poor handover and inadequate transmission of clinical information between shifts can result in patient harm. This study was designed to evaluate the impact of implementing a handover protocol on the quality of information exchanged in the trauma handover meetings in a UK hospital.

A prospective single centre observational study was performed at an acute NHS trust, using the Plan-Do-Study-Act (PDSA) methodology. Ten consecutive weekday trauma meetings, involving 43 patients, were observed to identify poor practices in handover. This data was used in conjunction with the Royal College of Surgeon's recommendations for effective handover (2007) to create a standard operating protocol (SOP). Following the implementation of the SOP, a further 8 consecutive weekday trauma meetings, involving a further 47 patients, were observed. The data collection was performed by 5 trained independent observers. The data was analysed using t test for quantitative variables and chi-square or Fisher's exact tests for categorical variables.

Eligibility criteria: Inclusion Criteria:

* All patients that were handed over were included in the study.

Exclusion Criteria:

* Nil.

Primary outcomes:
measure: To assess the efficacy of the handover of trauma patients going to theatre.
timeFrame: Up to 6 weeks.
measure: To assess the handover of neck of femur (NOF) fracture patients.
timeFrame: Up to 6 weeks.
measure: To determine if unwell patients were being handed over from the admissions list or patients already on the ward.
timeFrame: Up to 6 weeks.
Secondary outcomes:
Other outcomes:
Locations:
city: West Bromwich
country: United Kingdom
facility: Sandwell Hospital
Study officials:
affiliation: Audit Co-Ordinator Sandwell Hospital
name: Collette Samuels
role: STUDY_DIRECTOR
References:
Clinical trial NCT05279001: A Safety and Tolerability Study of Jaktinib
Official title: A Phase 1 Dose Escalation, Safety and Tolerability Study of Jaktinib in Patients With Primary Myelofibrosis (PMF) or Post-polycythemia Vera/Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) and Who Are Relapsed/ Refractory to a Marketed JAK Inhibitor
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Myelofibrosis
Lead sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Sponsor class: INDUSTRY
First posted: 2022-03-15
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This research study is studying a drug called Jaktinib as a possible treatment for Myelofibrosis.

Detailed description: This study is a Phase 1, single-arm, open-label, dose escalation trial, to evaluate the safety and tolerability of Jaktinib in patients with PMF or Post-PV/ET MF and who are relapsed/refractory to a marketed JAK inhibitor

Eligibility criteria: Inclusion Criteria:

* Diagnosis of myelofibrosis (primary, post-polycythemia vera, or post-essential thrombocythemia).
* Relapsed/refractory to a marketed (FDA approved) JAK inhibitor.
* At least 18 years of age.
* ECOG PS 0, 1, or 2.
* Expected life expectancy is greater than 24 weeks.

Exclusion Criteria:

* Any chemotherapy, immunomodulatory therapy, immunosuppressive therapy, corticosteroids, or growth factor treatment within 14 days prior to initiation of study drug.
* Major surgery or radiation therapy within 28 days prior to initiation of study drug.
* With suspected allergies to jaktinib or its excipient.
* Another clinical trial of a new drug or medical instrument within 3 months before screening.
* Females who are pregnant, currently breastfeeding, planning to become pregnant.
* Unable to adopt effective contraceptive methods during the study.

Primary outcomes:
measure: Safety of jaktinib hydrochloride tablets
timeFrame: At least 24 weeks, up to approximately 1 year for follow-up
measure: Dose-limiting toxicities (DLTs) of jaktinib hydrochloride tablets
timeFrame: 28 days
Secondary outcomes:
measure: Efficacy of jaktinib hydrochloride tablets
timeFrame: at least 24 weeks, up to approximately 1 year
measure: Efficacy of jaktinib hydrochloride tablets
timeFrame: at least 24 weeks, up to approximately 1 year
measure: Pharmacokinetic characteristics of jaktinib hydrochloride tablets
timeFrame: 7 days
measure: Pharmacokinetic characteristics of jaktinib hydrochloride tablets
timeFrame: 7 days
measure: Pharmacokinetic characteristics of jaktinib hydrochloride tablets
timeFrame: 7 days
measure: Pharmacokinetic characteristics of jaktinib hydrochloride tablets
timeFrame: 7 days
measure: Pharmacokinetic characteristics of jaktinib hydrochloride tablets
timeFrame: 7 days
measure: Pharmacokinetic characteristics of jaktinib hydrochloride tablets
timeFrame: 7 days
Other outcomes:
Locations:
city: Canton
country: United States
facility: Site 01
state: Ohio
Study officials:
References:
Clinical trial NCT05030701: Toxicity of Treatments for Non-tuberculous Mycobacterial Infections in Cancer Patients or Not
Official title: Toxicity of Treatments for Non-tuberculous Mycobacterial Infections in Cancer Patients or Not
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Mycobacterium
Cancer
Treatment Side Effects
Keywords: Mycobacterium
cancer
Treatment Side Effects
Lead sponsor: Centre Hospitalier Universitaire, Amiens
Sponsor class: OTHER
First posted: 2021-09-01
Enrollment: 43
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients infected with Nontuberculous mycobacteria, collected from CHU Amiens 2015 to 2020, extracted from the medical information service by the RUM (medical unit summary) with a diagnostic code ICD-10 which is the International Classification of diseases, commonly known as the international statistical classification of diseases and related health problems and Chapters A31.0, A31.8, A31.9.

Brief summary: Non-tuberculous mycobacteria (NTM) are increasingly common and have a poor prognosis: 5-year mortality can reach 40 to 50%, depending on the type of mycobacteria and the immune system of the host involved. Cancer patients are at higher risk of infectious morbidity and mortality, which may be due to disease-related immune dysfunction, immunosuppressive effects of chemotherapy, or long-term placement of a vascular catheter. However, data on the treatment of NTM species that cause infections and the disease characteristics of these pathogens in cancer patients are limited despite the growing cancer population worldwide. Recently, M. avium infections have been described in patients suffering from cancers (hematological or not), in particular in patients receiving checkpoint inhibitors. Although the proportion of M. avium pneumonia in retrospective series is low (0.8-2%), it has been shown that this population is younger, suffers less from sub-pulmonary pathology. (indicating immunosuppression in these patients) but are therefore treated less than non-cancerous subjects.

This retrospective study in CHU Amiens is searching on the number of side effects of NTM treatment in two groups (cancerous and no cancerous) to assess the cause of the decrease of NTM treatment in cancerous patients.


Eligibility criteria: Inclusion Criteria:

* Age equal or more than 18 years18
* Patients diagnosed by an infection with non-tuberculous mycobacteria according to ATS guidelines.
* Patients received the NTM treatment.

Exclusion Criteria:

* age less than 18 years
* Patients diagnosed by NTM without treatment.
* Patients with a positive sample of NTM but without infection.
* Exclusion of other disorders such as tuberculous.

Primary outcomes:
measure: variation of side effects number of non-tuberculous mycobacteria treatment between cancerous and non cancerous patient groups.
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Amiens
country: France
facility: CHU Amiens Picardie
state: Picardie
Study officials:
References:
Clinical trial NCT02399501: Sonohysterography , 3D Ultrasonography and Hysteroscopy in Assessment of Uterine Factor in Cases of Female Infertility
Official title: Sonohysterography and 3D Ultrasonography Versus Diagnostic Hysteroscopy in Assessment of Uterine Factor in Cases of Female Infertility
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Infertility
Keywords: 2D ultrasound
3D ultrasound
sonohysterography
hysteroscopy
Uterine factor of infertility
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2015-03-26
Enrollment: 100
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Prospective comparative study including 100 infertile patients with suspected uterine lesion. 2D ultrasound, sonohysterography , 3D ultrasound and hysteroscopy will be done to evaluate uterine cavity.

Detailed description: All patients will be examined by 2D transvaginal ultrasound using a 6.5 MHz probe (Sonoace 5000, Medison Co. Ltd, korea). Examination is performed after emptying of the bladder in dorsal lithotomy position.

Three dimensional ultrasound will be performed using Medison, Voulson 530 D-MT ultrasound machine (Medison Co. Ltd, Korea). The uterus is visualized in the longitudinal plane, the ultrasound probe is kept steady and the patient is asked to lie still on the examination bed.

Sonohysterography will be done after introduction of the catheter into the cervix, a twenty milliliter syringe which is prefilled with the distending media (saline) is then fitted to the catheter. The speculum is removed and endovaginal probe is introduced in the posterior vaginal fornix. The uterus is then visualized in the longitudinal plane to demonstrate the endometrial cavity and the catheter. Once this is possible, sterile saline is slowly injected through the catheter into the uterine cavity; up to ten milliliter of saline is usually enough for the procedure.

Hysteroscopy will be done under general anesthesia. The hysteroscopy is rigid continuous flow diagnostic hysteroscopy . It has a 30º panoramic optic which is 4 mm in diameter and the diagnostic continuous flow outer sheath is 6.5 mm in diameter.

Eligibility criteria: Inclusion Criteria:

* Suspected uterine factor of infertility

Exclusion Criteria:

* tubal, ovarian or male factor of infertility

Primary outcomes:
measure: detection of uterine lesion
timeFrame: at time of hystroscopy
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ahmed Maged
Study officials:
affiliation: Kasr Alainy medical school
name: Ahmed Maged, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01930201: Caudal Epidural Block for Postoperative Analgesia in Adolescents Following Major Hip Surgery.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Major Orthopedic Hip Surgery
Lead sponsor: Nationwide Children's Hospital
Sponsor class: OTHER
First posted: 2013-08-28
Enrollment: 32
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who had major orthopedic hip surgery.

Brief summary: This retrospective chart review will demonstrate the feasibility of performing caudal epidural blockade in adolescents undergoing major orthopedic hip surgery and provide information regarding the feasibility of this technique's use on a regular basis.


Eligibility criteria: Inclusion Criteria:

* Adolescents that underwent major orthopedic hip surgery.

Exclusion Criteria:

* None.

Primary outcomes:
measure: Pain
timeFrame: During 1st 24 hours post-op
Secondary outcomes:
measure: Pain medication requirement
timeFrame: During 1st 24 hours post-op
measure: Antiemetic medication requirement
timeFrame: During 1st 24 hours post-op
Other outcomes:
Locations:
city: Columbus
country: United States
facility: Nationwide Children's Hospital
state: Ohio
Study officials:
References: